Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."
Source: hcplive.com